Alleged Failure to Disclose Drug Safety Issues
Cornerstone Research was retained by a pharmaceutical company facing securities litigation after it withdrew a drug from the market because of safety concerns.
ICC Arbitration Involving Commercially Reasonable Efforts to Develop and Commercialize a Drug
An ICC arbitration tribunal determined that the claimant did not materially breach its license agreement with the respondent, leaving the agreement in full effect.
In re Niaspan Antitrust Litigation
The judge denied class certification in this pharmaceutical pay-for-delay multidistrict litigation.
COVID-19 Implications for Pharmaceutical Litigation
Darius Lakdawalla of the University of Southern California discusses the economics of pharmaceutical markets and the impacts of COVID-19 from the manufacturer perspective.
2020 IAM Guide to Leading Patent Professionals
Intellectual Asset Management (IAM) names Henry Grabowski of Duke University and Matthew Lynde of Cornerstone Research in its annual list of leading expert witnesses on patent issues in the United…
In re Intuniv Antitrust Litigation
The judge denied class certification in this pharmaceutical pay-for-delay case brought by a class of indirect purchasers.
Cigna’s Acquisition of Express Scripts
The parties completed a $67 billion merger after receiving clearance from the U.S. Department of Justice and state departments of insurance.
Hsu et al. v. Puma Biotechnology Inc. et al.
Positive jury verdict in rare securities class action trial.
Competition Law and Economics in Pharmaceutical Markets
Cornerstone Research hosted expert forums in London and Brussels to examine recent competition cases in Europe.
Product Hopping
Pharmaceutical manufacturers have been accused of engaging in product hopping by introducing modified versions of branded drugs nearing patent expiry while simultaneously withdrawing the older drugs to hinder generic substitution.
How can we help you?
If you are looking for a publication not on our website, contact us.
